Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, aligning with current market conditions while maintaining its long-term strategy [1][2][3] Group 1: Warrant Amendment Details - The exercise price of the warrant has been reduced from US$4.00 per share to US$2.00 per share [2] - The minimum closing price required to trigger a forced exercise has been lowered from US$6.00 to US$3.00 [2] - All other terms of the warrant remain unchanged [2] Group 2: Company Overview and Strategy - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [3] - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the longevity sector [3] - EUDA is committed to transforming healthcare from reactive treatment to proactive, longevity-focused care through innovative and accessible health solutions [3]

Core Viewpoint - EUDA Health Holdings Limited has amended its warrant agreement with Streeterville Capital, reducing the exercise price and minimum closing price for forced exercise, which may enhance the attractiveness of the warrant for investors [3]. Group 1: Warrant Transaction Background - On November 26, 2025, EUDA entered into a securities purchase agreement with Streeterville Capital for a warrant exercisable into up to 2,000,000 newly issued ordinary shares for an aggregate purchase price of US$100,000 [2]. - The warrant was issued on December 4, 2025, and can be exercised for cash for 90 days from the issuance date, after which a cashless exercise will occur if not exercised [2]. Group 2: Amended Terms - The Warrant Amendment, effective December 16, 2025, reduces the exercise price from US$6.00 to US$4.00 per share [3]. - The minimum closing price required to trigger a "Forced Exercise" has been reduced from US$7.50 to US$6.00 [3]. Group 3: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China [4]. - The company aims to address the healthcare needs of over 1.8 billion people in the region, with a strategic focus on the growing longevity sector [4]. - EUDA is positioned to transform regional healthcare from reactive treatment to proactive, longevity-focused care [4].

Core Insights - EUDA Health Holdings Limited is set to launch EUDA Helixé 2.0 in January 2026, representing a significant upgrade in its premium vitality and longevity supplement line [1][6] Product Enhancements - The new formulation includes a 20% increase in New Zealand sourced deer placenta powder, raising the dosage from 100 mg to 120 mg, enhancing its potency [2] - L-glutathione has been replaced with D-alpha-tocopherol (Vitamin E, 1.4 mg equivalent) to improve antioxidant stability and support skin health [2] - Advanced encapsulation technology has been implemented to enhance stability, absorption efficiency, and shelf life, utilizing a nano-based delivery system for smaller capsule sizes [3][8] Packaging and Design - A new proprietary bottle design has been introduced to reflect the premium positioning of EUDA Helixé, enhancing product protection and brand identity [4] Market Expansion - EUDA Helixé 2.0 has received New Zealand Halal certification, facilitating broader international distribution and entry into Muslim markets across Southeast Asia and the Middle East [5] Strategic Positioning - The launch of EUDA Helixé 2.0 underscores the company's commitment to innovation and global wellness solutions, positioning it as a core offering within EUDA's health and longevity ecosystem [6][7] - The company aims to address the healthcare needs of over 1.8 billion people in Asia, focusing on the growing longevity sector as populations age [9]

Core Insights - EUDA Health Holdings Limited is integrating the QB utility token into its digital health and rewards platform, enhancing customer engagement and loyalty within its healthcare ecosystem [1][2] Group 1: Strategic Integration - The QB utility token will allow customers and agents to earn and redeem tokens for various EUDA healthcare offerings, creating a unified digital engagement platform [2] - This integration supports EUDA's long-term vision of a modern healthcare ecosystem that combines wellness, technology, and user engagement [2][5] Group 2: Technology Architecture - The integration utilizes smart contract logic to manage token issuance, vesting schedules, and ecosystem governance, ensuring secure interactions through an API layer [3] - All transactions are recorded as non-monetary exchanges, maintaining traceability within the QB ecosystem [3] Group 3: Token and Financial Structure - The QB utility token is built on Binance Smart Chain and is designed for interoperability with stablecoins like USD1, which is redeemable 1:1 with the US dollar [4] - USD1 is backed by reserves in treasury bills and cash equivalents, ensuring institutional transparency and efficiency [4] Group 4: Company Overview - EUDA Health Holdings Limited focuses on non-invasive healthcare in Asia, particularly in Singapore, Malaysia, and China, aiming to lead in the longevity sector [6] - The company addresses the healthcare needs of over 1.8 billion people in a region experiencing significant demographic shifts, with over 30% of the population aging rapidly [6]

Core Insights - EUDA Health Holdings Limited is launching an integrated digital health and rewards platform utilizing a utility cryptocurrency called QB, set to launch in January 2026 [1][2] - The QB cryptocurrency will facilitate payments, rewards, and access to EUDA's healthcare products and services, enhancing the connection between healthcare and digital finance [2][3] - This initiative aims to transform healthcare engagement into tangible economic and health benefits, promoting a unified ecosystem that combines wellness products and digital assets [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [4] - The company aims to lead the transformation from reactive medical treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [4]

Core Viewpoint - EUDA Health Holdings Limited has entered into a securities purchase agreement with Streeterville Capital for a convertible warrant, aiming to strengthen its capital position and support growth strategies in the non-invasive healthcare market in Asia [1][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based non-invasive healthcare provider focusing on Singapore, Malaysia, and China, with a mission to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care [5]. - The company targets the fast-growing longevity sector, addressing the healthcare needs of over 1.8 billion people in the region, where more than 30% of the population is aging rapidly [5]. Financial Details - The securities purchase agreement involves the sale of a convertible warrant for an aggregate purchase price of US$100,000, which is exercisable for up to 2,000,000 newly issued ordinary shares at an exercise price of US$6.00 per share [1][3]. - The warrant can be exercised for cash within a 90-day period, with conditions allowing the company to require Streeterville Capital to exercise the warrant under specific trading volume and price conditions [3]. Strategic Intent - The CEO of EUDA emphasized that the warrant financing provides flexibility to invest in high-return initiatives, including new centers, partnerships, and technology, to expand the company's footprint in Asia's non-invasive healthcare market [4].

Core Viewpoint - EUDA Health Holdings Limited has secured exclusive worldwide distribution rights for a next-generation immune health supplement, enhancing its wellness product portfolio and positioning itself in the molecular precision wellness market [1][7]. Group 1: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [1][8]. - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [8][10]. Group 2: Product Details - The newly acquired supplement, branded as Euda Helixé, is designed to modulate gene expression, enhancing metabolism, boosting vitality, and supporting longevity through advanced epigenetic technology [2][3]. - The supplement combines premium-grade ingredients and utilizes a capsule delivery system that ensures active ingredients survive stomach acid for optimal absorption [4][9]. Group 3: Market Strategy - EUDA plans to initially market and sell the supplement in Singapore, Malaysia, and China, with future expansion into other markets [2]. - The company anticipates generating sales of approximately 500,000 bottles over the next 12 months, leveraging its strong regional ecosystem and distribution capabilities [7]. Group 4: Scientific Background - The supplement is developed by Chemokine Pte. Ltd., founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [6]. - The formulation builds on prior scientific advancements and proven platforms to deliver molecular-level wellness support [4].